The animal health specialist suffered in 2022, but the accounts and the new strategic plan were well received. Vetoquinol’s annual turnover was 5% below consensus expectations at 521 million euros, down 0.8% organically, slowed down by a third and final quarter with respective declines of 4.5 and 2.4%, causing the stock to fall. The publication […]
Vetoquinol: after a mixed year, the outlook is improving Read More »
Virbac: the stock falls after a significant profit warning The veterinary laboratory finds itself in operational difficulty at the start of the financial year. He was also the victim of a cyberattack. The high basis of comparison made this first part of the year complicated for Virbac, after a good 2022 vintage. The first quarter
Virbac: the stock falls after a significant profit warning Read More »
The veterinary laboratory reported half-yearly activity slightly better than anticipated. On the stock market, the title benefits. While the clouds were accumulating over the animal health specialist, and its stock was suffering, the publication of the half-yearly turnover gave the price some breathing room. Indeed, while Virbac revised its annual targets sharply downward at the
Action advice – Virbac: the market relieved by the good performance of sales Read More »
The group did not escape the gloom in the animal health sector in the first half of 2023. A recovery is expected, but the profitable growth targeted for the year is fading. The Vetoquinol stock has never really recovered from the drop suffered a year ago, after the publication of disappointing 2022 half-year accounts. While
Action advice – Vetoquinol: a first half more difficult than expected Read More »
